BioCentury
ARTICLE | Clinical News

Synthetic slides after dropping Trimesta for RRMS

February 3, 2016 3:08 AM UTC

Synthetic Biologics Inc. (NYSE-M:SYN) fell $0.21 (14%) to $1.28 on Tuesday after it said it terminated a license with the Regents of the University of California to IP covering the use of Trimesta, an oral estriol, as an adjunct therapy to treat relapsing-remitting multiple sclerosis.

The company said independent CROs evaluated data from an investigator-sponsored Phase II trial and concluded there were no significant differences between patients receiving Trimesta plus Copaxone glatiramer acetate from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) vs. placebo plus Copaxone at 12 and 24 months. Synthetic had previously reported that Trimesta plus Copaxone led to a non-significant 32% reduction in annualized relapse rate (ARR) at two years, the trial's primary endpoint, vs. placebo plus Copaxone (see BioCentury Extra, April 30, 2014). ...